IUPAC name
({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid
SMILES
C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O
Compound class
Antiviral Agents; Anti-HIV Agents; Reverse Transcriptase Inhibitors; Antiinfectives for Systemic Use; Direct Acting Antivirals; Antivirals for Systemic Use; Nucleoside and Nucleotide Reverse Transcriptase Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP1A2 Inducers;
Therapeutic area
Tenofovir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 2 years of age and older. It is also indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
Common name
Tenofovir
IUPAC name
({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid
SMILES
C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O
INCHI
InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1
FORMULA
C9H14N5O4P
Common name
Tenofovir
IUPAC name
({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid
Molecular weight
287.212
clogP
-1.933
clogS
-0.528
HBond Acceptor
7
HBond Donor
4
Total Polar Surface Area
136.38
Number of Rings
2
Rotatable Bond
5
